Skip to main content

Table 1 Patient, tumor, and treatment characteristics at initial planning (CT0)

From: A Nomogram to predict parotid gland overdose in head and neck IMRT

ID Gender Age TNM Tumor sublocation Chemotherapy Volume (cm3) Mean planned PG dose (Gy) Xerostomia NTCP (%) [23, 24]
CTV70 ILP CLP ILP CLP ILP CLP
1 M 77 T4N0 Tonsil Cetuximab 45.2 52.1 48.6 30.2 31.1 27.1 28.9
2 F 61 T2N2 Base of tongue CDDP 26.3 31.1 27.5 31.4 26 29.7 19.1
3 M 70 T3N2c Oropharynx CDDP 181.5 24.9 20.7 37.9 31.1 45.1 29.1
4 F 66 T2N2c Oropharynx Cetuximab 107.2 27.8 23.4 32.9 27.9 33.1 22.5
5 M 57 T3N0 Velum CDDP 62.4 20.7 18 28.1 27.8 23 22.3
6 M 67 T3N2c Base of tongue CDDP 156.2 24.5 22.7 30.8 29.4 25.4 22.1
7 M 52 T4N2a Tonsil Cetuximab 165.1 N/A 21.6 N/A 28.7 N/A 24
8 M 67 T4N1 Base of tongue CDDP 139.3 22 19.3 30.7 29.2 28 25
9 F 65 T3N3 Base of tongue CDDP 237.5 23.9 20.2 42.4 31.1 56.1 29
10 F 65 T4N3 Oropharynx CDDP 257.9 N/A 24.5 N/A 35.2 N/A 38.5
11 M 50 T4N2c Oropharynx CDDP 434.5 N/A 17.7 N/A 36.3 N/A 41.1
12 M 53 T3N0 Base of tongue CDDP 14.4 16.6 23.3 41.3 24.2 53.6 16.3
13 M 73 T3N2c Oropharynx Cetuximab 147 29.4 29.2 54.6 32.2 82.1 31.4
14 M 56 T3N0 Epiglottic Cetuximab 14 22.8 29.2 19.7 9.2 10.3 2.7
15 M 75 T2N2a Oropharynx Cetuximab 76.3 20.3 22.4 29.4 29.1 25.6 25
16 M 57 T3N0 Oropharynx CDDP 46.5 23.8 31.2 32.1 31.2 29.3 31.3
17 M 64 T3N2c Epiglottic CDDP 109.8 23.5 15.6 39.6 17.3 49.3 7.8
18 M 55 T1N2b Tonsil CDDP 31 20.2 20.8 25.7 23.63 18.7 15.3
19 M 65 T4N0 Velum CDDP 10.1 23.7 25.3 28.6 28.2 24 23.2
20 M 56 T4N2b Pharyngeal wall CDDP 150 32.4 26.8 45 24.4 62.8 16.6
  1. M male, F female, CTV70 clinical target volume receiving 70Gy, ILP ipsilateral parotid glands, CLP contralateral parotid glands, CDDP cisplatin, NTCP normal tissue complication, PG parotid gland, N/A not applicable (PGs included in the CTV)
  2. The NTCP Lyman Kutcher Burman (LKB) model (n = 1, m = 0.4, and median toxic dose [TD50] = 39.9) [23, 24] defined the risk of xerostomia as a salivary flow ratio <25 % of the pretreatment one